SPECIALTY QUANTITY LIMIT PROGRAM

ZAVESCA (miglustat)

PROGRAM DESCRIPTION Ι.

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for type 1 Gaucher disease fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication*	Standard Limit	FDA-recommended dosing
Zavesca (miglustat) 100 mg capsules	90 capsules per 30 days	100 mg orally three times a day

*The limit may apply to the generic equivalent medications.

III. REFERENCES

1. Zavesca [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; November 2017.

Specialty Quantity Limit miglustat-Zavesca 1694-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

